Date: 7th September 2026

Financial Performance Summary

Quarterly Financial Results (Consolidated)

| Particulars | Q1 FY27 | Q1 FY26 | Q4 FY26 |

| Total Income* | ₹411.48 Cr | ₹100.47 Cr | ₹565.41 Cr |

| EBITDA* | ₹103.68 Cr | (₹14.50 Cr) | ₹163.51 Cr |

| EBITDA Margin (%) | 25.20% | (14.43%) | 28.92% |

| PAT | ₹52.74 Cr | (₹23.94 Cr) | ₹95.83 Cr |

| PAT Margin (%) | 12.82% | (23.83%) | 16.95% |

*Total Income & EBITDA includes other income

Key Financial Highlights

  • Q1 FY27 Total Income stood at ₹411.48 Cr as against ₹100.47 Cr in Q1 FY26, representing significant growth
  • Q1 FY27 EBITDA showed remarkable improvement at ₹103.68 Cr profit compared to a loss of ₹14.50 Cr in Q1 FY26
  • EBITDA Margin improved to 25.20% from negative 14.43% in Q1 FY26
  • PAT turned positive at ₹52.74 Cr versus a loss of ₹23.94 Cr in Q1 FY26
  • PAT Margin stood at 12.82% compared to negative 23.83% in Q1 FY26

Operational Performance Metrics

Key Operating Metrics

| KPIs | Q1 FY27 | Q1 FY26 | Q4 FY26 |

| Truenat devices sold (Units) | 164 | 216 | 1,158 |

| Truenat test kits sold (Mn Units) | 6.24 | 0.79 | 5.38 |

| Domestic revenue mix (%) | 83.52% | 81.84% | 93.97% |

| Export revenue mix (%) | 16.48% | 18.16% | 6.03% |

Performance Drivers

  • Growth was driven by continued volume of Truenat test-kit consumption
  • Margin trajectory reflects operating leverage on rising test-kit volumes
  • International go-to-market build-out investments partly offset margin improvements
  • The company noted that export orders pertaining to Q4 FY26, amounting to approximately ₹57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognized in Q1 FY27

Business and Strategic Updates

Capacity Utilization

  • FY26 device utilization at 42%
  • FY26 test-kit utilization at 58%
  • Company entered FY27 with meaningful capacity headroom

Product Pipeline

  • Pipeline of 34 additional assays across 22 diseases remains on track
  • Expansion beyond infectious disease into oncology and other non-communicable areas

International Expansion

  • Deepening presence across Africa and Southeast Asia
  • Entering Latin America markets
  • Progressing regulatory pathways in developed markets, including CE-IVDR for CTNG Test

Capital Deployment

  • Deployment of net issue proceeds from recent listing (August 17, 2026) underway
  • Capex allocation for automation and building R&D facility in Bengaluru

Management Commentary Highlights

Mr. Sriram Natarajan, Executive Director & Chief Executive Officer, emphasized:

  • FY27 is a milestone year marking transition to a listed company
  • Business has non-linear revenue profile with performance varying across quarters
  • Assessment should be on full-year basis rather than quarterly
  • Growth led by test-kit consumption across 12,500+ Truenat® devices sold in 90+ countries
  • Focus on disciplined execution, sustained R&D intensity and improving cash flow quality

Company Background

Molbio Diagnostics Limited is an innovative point-of-care diagnostics company headquartered in Goa

  • Flagship innovation: Truenat® platform - portable, battery-operated real-time PCR platform
  • Protected by patents in more than 100 countries
  • Supports molecular testing for 30 diseases through 43 assays
  • Tuberculosis test is among only two rapid molecular diagnostic platforms globally endorsed by WHO
  • As of March 31, 2026: 12,500+ Truenat® devices installed in 90+ countries
  • Expanded product portfolio through subsidiaries (Prognosys Medical Systems and OptraScan Inc.) and strategic partnerships with UE Lifesciences into radiology, digital pathology and breast health screening